Selectivity of C−H vs. C−F Bond Oxygenation by Homo- and Heterometallic Fe_4, Fe_3Mn, and Mn_4 Clusters by De Ruiter, Graham et al.
 S1 
Supporting Information 
 
 
Selectivity of C−H vs. C−F Bond Oxygenation in Homo- and Heterometallic Fe4, 
Fe3Mn, and Mn4 Clusters 
 
Dr. Graham de Ruiter,[a] Kurtis M. Carsch,[a] Michael K. Takase, and Prof. Theodor Agapie*[a]  
 
[a]Department of Chemistry and Chemical Engineering. California Institute of Technology; Pasadena, 
California 91125, United States.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 S2 
Table of Contents. 
 
General Considerations. ............................................................................................................................. 4 
Physical Methods. ........................................................................................................................................ 4 
Synthetic Procedures .................................................................................................................................. 6 
Synthesis of sodium 3-(2-fluorophenyl)pyrazolate (NaHFArPz) ............................................................ 6 
Synthesis of [LFe3(HFArPz)3OFe][OTf]2 (1) ............................................................................................... 6 
Synthesis of [LFe3(HFArPz)3OMn][OTf]2 (2) .............................................................................................. 7 
Synthesis of [LMn3(HFArPz)3OMn][OTf]2 (3) ............................................................................................ 7 
Synthesis of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4) ................................................................................. 8 
Synthesis of [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5) ............................................................................... 8 
Synthesis of [LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6) ................................................................................ 9 
Synthesis of [LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7) .............................................................................. 9 
Addition of sPhIO to [LFe3(HFArPz)3OFe][OTf]2 (1) ................................................................................ 10 
Addition of sPhIO to [LFe3(HFArPz)3OMn][OTf]2 (2) .............................................................................. 10 
Addition of sPhIO to [LMn3(HFArPz)3OMn][OTf]2 (3) ............................................................................. 10 
Preparation Calibration Curve of Complexes 4 and 5. ............................................................................... 11 
Preparation of Calibration Curve of Complexes 6 and 7. ........................................................................... 11 
Figure S1. 1H NMR spectrum (400 MHz) of NaHFArPz .......................................................................... 13 
Figure S2. 13C NMR spectrum (125 MHz) of NaHFArPz ......................................................................... 13 
Figure S3. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)3OFe][OTf]2 (1) ......................................... 14 
Figure S4. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)3OMn][OTf]2 (2) ........................................ 14 
Figure S5. 1H NMR spectrum (300 MHz) of [LMn3(HFArPz)3OMn][OTf]2 (3) ...................................... 15 
Figure S6. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4) ........................... 15 
Figure S7. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5) ......................... 16 
Figure S8. Comparison of the 1H NMR spectrum of the crude reaction mixture with the 1H NMR 
spectrum of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (5) ................................................................................ 16 
Figure S9. 1H NMR spectra (300 MHz) of various ratios of complexes 4 and 5 ...................................... 17 
Figure S10. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6) ........................ 17 
Figure S11. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7) ...................... 18 
Figure S12. Comparison of the 1H NMR spectrum of the crude reaction mixture with the 1H NMR 
spectrum of a mixture of complexes 6 and 7 in a 2:4 ratio ......................................................................... 18 
Figure S13. 1H NMR spectra (300 MHz) of various ratios of complexes 6 and 7 .................................... 19 
Figure S14. 1H NMR spectrum (300 MHz) of the crude reaction mixture after treating 3 with sPhIO for 
60 minutes. .................................................................................................................................................. 19 
Figure S15. Cyclic Voltammogram of Complex 1 .................................................................................... 20 
Figure S16. Cyclic Voltammogram of Complex 2 .................................................................................... 20 
Figure S17. Cyclic Voltammogram of Complex 3 .................................................................................... 21 
Figure S18. ESI-MS spectrum of the crude reaction mixture after treating 1 with sPhIO ......................... 22 
Figure S19.	ESI-MS spectra of various ratios of complexes 4 and 5. ....................................................... 23 
 S3 
Figure S20. Calibration curve and experimental C(sp2)–H vs. C(sp2)–F ratio after treating complex 1 with 
sPhIO as determined by 1H NMR and ESI-MS ........................................................................................... 24 
Figure S21.	ESI-MS spectrum of the crude reaction mixture after treating 2 with sPhIO ......................... 25 
Figure S22. ESI-MS spectra of various ratios of complexes 6 and 7 ........................................................ 26 
Figure S23. Calibration curve and experimental C(sp2)–H vs. C(sp2)–F ratio after treating complex 2 with 
sPhIO as determined by 1H NMR and ESI-MS.   ........................................................................................ 27 
Figure S24. ESI-MS spectrum of the crude reaction mixture after treating 3 with sPhIO ......................... 28 
Figure S25. Crystal structure of [LFe3(HFArPz)3OFe][OTf]2 (1). ............................................................ 29 
Special refinement details for complex 1. ................................................................................................... 29 
Figure S26. Crystal structure of [LFe3(HFArPz)3OMn][OTf]2 (2). ........................................................... 30 
Special refinement details for complex 2. ................................................................................................... 30 
Figure S27. Crystal structure of [LMn3(HFArPz)3OMn][OTf]2 (3). ......................................................... 31 
Special refinement details for complex 3. ................................................................................................... 31 
Figure S28. 1H NMR spectrum (300 MHz) of the crude reaction mixture upon treating 1 with sPhIO for 
60 minutes, in the presence of an internal standard (CoCp2; 71.4 mM) in a glass capillary. ..................... 31 
Figure S29. 1H NMR spectrum (300 MHz) of 4 with sPhIO for 60 minutes, in the presence of an internal 
standard (CoCp2; 71.4 mM) in a glass capillary. ........................................................................................ 31 
Table S1. Selected bond distances and angles for complex 1–3 ................................................................ 33 
Table S2. Crystal and refinement data for complexes 1–3 ......................................................................... 34 
References .................................................................................................................................................. 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 S4 
General Considerations. 
 
All reactions were performed at room temperature in an N2-filled M. Braun Glovebox or by using 
standard Schlenk techniques unless otherwise specified. Glassware was oven dried at 140 °C for at least 
2h prior to use, and allowed to cool under vacuum. All reagents were used as received unless otherwise 
stated. Iodosobenzene (PhIO), 2-(tertbutylsulfonyl)iodosobenzene (sPhIO), 3-(2-fluorophenyl)-1H-
pyrazole (HFArPzH), 2-(1H-pyrazol-3-yl)phenolate (NaOArPzH), 2-(1H-pyrazol-3-yl)-3-fluorophenolate 
(NaOFArPzH), LFe3(OAc)(OTf)2, and LMn3(OAc)(OTf)2 were synthesized according to published 
procedures.[S1-7] Caution! Iodosobenzene is potentially explosive and should be used only in small 
quantities. 2-fluoroacetophenone, Na(N(SiMe3)2), and AgOTf, were purchased from Sigma Aldrich, 
Oakwood Chemicals and Strem Chemicals. All pyrazoles were sublimed before use. Anhydrous 
tetrahydrofuran (THF) was purchased from Aldrich in 18 L Pure-PacTM containers. Anhydrous CH2Cl2, 
diethyl ether, hexane and THF were purified by sparging with nitrogen for 15 minutes and then passing 
under nitrogen pressure through a column of activated A2 alumina. Anhydrous 1,2-dimethoxyethane 
(DME) was dried over sodium/benzophenone and vacuum-transferred onto molecular sieves. The 1H and 
13C{1H} NMR spectra were recorded at 400.13, and 100.62 MHz on a Bruker AscendTM 400 MHz 
spectrometer equipped with prodigy cryoprobe, or at 300.13, 282.36 (19F), and 75.47 MHz, on a Varian 
300 MHz spectrometer. All chemical shifts (δ) are reported in ppm, and coupling constants (J) are in Hz. 
The 1H and 13C{1H} NMR spectra were referenced using residual solvent peaks in the deuterated solvent. 
The 19F chemical shifts are reported relative to the internal lock signal. Deuterated solvents (CD2Cl2 and 
CD3CN) were purchased from Cambridge Isotope Laboratories, dried over calcium hydride, degassed by 
three freeze-pump-thaw cycles and vacuum-transferred prior to use. The UV-vis spectra were recorded on 
a Varian Cary Bio 50 spectrophotometer. Fast atom bombardment-mass spectrometry (FAB-MS) analysis 
was performed with a JEOL JMS-600H high resolution mass spectrometer. Elemental analyses were 
performed at Caltech. 
 
Physical Methods. 
 
Electrochemical measurements. CVs were recorded with a Pine Instrument Company AFCBP1 
bipotentiostat using the AfterMath software package. All measurements were performed in a three-
electrode cell configuration that consisted of 1) a glassy-carbon (ø = 3.0 mm) working electrode, 2) a Pt 
wire as counter electrode, and 3) an Ag wire as reference electrode. All electrochemical measurements 
were performed at RT in an M. Braun N2-filled glovebox. Dry dichloromethane containing 0.1 M 
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nBu4NPF6 was used as the electrolyte solution. The ferrocene/ferrocenium (Fc/Fc+) redox couple was used 
as an internal standard for all measurements. 
 
X-ray crystallography. For compounds 1 and 2, low-temperature (100 K) diffraction data (φ-and ω-
scans) were collected on a Bruker AXS D8 VENTURE KAPPA diffractometer coupled to a PHOTON 
100 CMOS detectors with Mo Kα radiation (λ = 0.71073 Å) or with Cu Kα (λ = 1.54178 Å). For 
compound 3, low-temperature (100 K) diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to an APEX II CCD detector with graphite monochromated Mo 
Kα radiation (λ = 0.71073 Å). All diffractometer manipulations, including data collection, integration, 
and scaling were carried out using the Bruker APEXII software.[S8] Absorption corrections were applied 
using SADABS.[S9] Structures were solved by direct methods using SHELXS[S10] and refined against F2 
on all data by full-matrix least squares with SHELXL-2014[S11] using established refinement 
techniques.[S12] All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were included 
into the model at geometrically calculated positions and refined using a riding model. The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms they are 
linked to (1.5 times for methyl groups). All disordered atoms were refined with the help of similarity 
restraints on the 1,2- and 1,3-distances and displacement parameters as well as enhanced rigid bond 
restraints for anisotropic displacement parameters. Due to the size of compounds (1–3), most crystals 
included solvent accessible voids, which tended to contain disordered solvent. In most cases, this disorder 
could be modeled satisfactorily Furthermore, the long-range order of these crystals and amount of high 
angle data was in some cases not ideal, due to desolvation of the crystals and/or solvent disorder. These 
disordered solvent molecules were largely responsible for the alerts generated by the checkCIF protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 S6 
Synthetic Procedures 
 
Sodium 3-(2-fluorophenyl)pyrazolate (NaHFArPz). In the glovebox, to a solution of 3-(2- 
fluorophenyl)-1H-pyrazole (3.94 g.; 24.0 mmol) in THF (20 mL) was added a solution of sodium 
bis(trimethylsilyl)amide (5.35 g; 29.0 mmol) in THF (5 mL). The color darkens to light yellow and the 
homogenous solution was stirred for 2 h. The solvent was removed under reduced pressure to yield a 
yellow oil. Addition of hexane (50.0 mL), and stirring for 16 h, resulted in the formation of a white 
precipitate, which was collected on a medium porosity frit. The solid was washed with hexane (3 × 20.0 
mL) and dried under reduced pressure to yield of sodium 3-(2-fluorophenyl)pyrazolate (2.0 g; 50 %) as an 
off-white powder. 1H NMR (400 MHz, CD3CN) δ 7.94 (td, J = 7.8, 1.7 Hz, 1H; m-ArH), 7.61 (d, J = 1.6 
Hz, 1H; CHCHNH), 7.18 – 7.05 (m, 3H; o-ArH, m-ArH, and p-ArH), 6.54 (dd, J = 3.9, 1.6 Hz, 1H; 
CHCHNH). 13C NMR (101 MHz, CD3CN) δ 159.93 (d, J = 243.8 Hz; o-ArCF), 146.12 (d, J = 3.8 Hz; 
NCHCHC), 140.89 (d, J = 1.7 Hz; NCHCHC), 129.29 (d, J = 5.3 Hz; p-ArC), 127.04 (d, J = 8.4 Hz; o-
ArC), 125.85 (d, J = 12.5 Hz; i-ArC), 125.05 (d, J = 3.1 Hz; m-ArC), 116.56 (d, J = 23.3 Hz; m-ArC), 
103.94 (d, J = 6.7 Hz; NCHCHC). 19F NMR (376 MHz, CD3CN) δ -118.27 (o-ArF). 
 
[LFe3(HFArPz)3OFe][OTf]2 (1). In the glovebox, a suspension of LFe3(OAc)(OTf)2 (4090 mg, 3.0 
mmol) in THF (100 mL) was frozen in the cold well. To the thawing suspension was added a thawing 
solution of NaHFArPz (1820 mg, 10.0 mmol) in THF (6 mL). The color changed immediately to orange 
and the suspension became homogeneous during the course of 1 hour. The solution was stirred for a total 
of 2 hours, and a fine suspension was formed. Here after iodosobenzene (PhIO, 671 mg, 3.0 mmol) was 
added as a solid, and the mixture changed to orange brown immediately and became homogenous after 
0.5 h. The solution was stirred for 1 h. and a brown precipitate formed. To the suspension was added 
Fe(OTf)2 (1562 mg, 4.5 mmol) as a solid. The suspension was stirred for 24 h and subsequently filtered 
over a bed of Celite (0.5 cm) on a medium porosity glass frit. The remaining brown solid was dissolved in 
dichloromethane, filtered, and the solvent removed under reduced pressure to yield a brown solid (1763 
mg). The solid was crystallized from acetonitrile/diethyl ether to yield [LFe3(PhPz)3OFe][OTf]2 as a 
brown crystals. Yield 1362 mg (24%). X-ray quality crystals were obtained by diffusing diethyl ether into 
a concentrated solution of 1 in acetonitrile. 1H NMR (300 MHz, CD2Cl2) δ 117.5 (br), 70.5 (s), 67.67 (s), 
54.3 (br), 49.2 (s), 44.1 (s), 43.6 (s), 17.04 (s), 15.8 (s), 14.6 (s), 12.9 (s), 11.0 (s), -3.56 (s), -7.8 (s). 19F 
NMR (282 MHz, CD2Cl2) δ -78.1 (s). UV-Vis (CH2Cl2) [ε (M-1 cm-1)]: 243 nm (2.43 × 105), 426 nm (2.01 
× 104). Anal. calcd. (%) for C86H57F9Fe4N12O10S2: C 55.03, H 3.06, N 8.96; found: C 54.59, H 3.10, N 
8.68. 
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[LFe3(HFArPz)3OMn][OTf]2 (2). In the glovebox, a suspension of LFe3(OAc)(OTf)2 (4210 mg, 3.0 
mmol) in THF (100 mL) was frozen in the cold well. To the thawing suspension was added a thawing 
solution of NaHFArPz (1902 mg, 10.0 mmol) in THF (6 mL). The color changed immediately to orange 
and the suspension became homogeneous during the course of 1 hour. The solution was stirred for a total 
of 2 hours. Here after iodosobenzene (PhIO, 664 mg, 3.0 mmol) was added as a solid, and the mixture 
changed to orange brown immediately and became homogenous after 0.5 h. The solution was stirred for 1 
h. and a brown precipitate formed. To the suspension was added Mn(OTf)2•2MeCN (1926 mg, 4.5 mmol) 
as a solid. The suspension was stirred for 24 h and the solvent removed under reduced pressure. To the 
remaining brown solid was added DME (40 mL), and the resulting suspension was stirred for 16 h, and 
subsequently filtered over a bed of Celite (0.5 cm) on a medium porosity glass frit. The remaining brown 
solid was dissolved in dichloromethane, filtered, and the solvent removed under reduced pressure to yield 
a brown solid (2162 mg). The solid was crystallized from acetonitrile/diethyl ether to yield 
[LFe3(PhPz)3OMn][OTf]2 as a brown crystals. Yield 1736 mg (31%). X-ray quality crystals were 
obtained by diffusing diethyl ether into a concentrated solution of 2 in acetonitrile. 1H NMR (300 MHz, 
CD2Cl2) δ 119.0 (br), 78.7 (br), 71.6 (s), 69.7 (s), 53.8 (s), 51.4 (s), 45.4 (s), 15.3 (s), 13.4 (s), -1.9 (s). 19F 
NMR (282 MHz, CD2Cl2) δ -78.1 (s). UV-Vis (CH2Cl2) [ε (M-1 cm-1)]: 244 nm (1.99 × 105), 438 nm (1.48 
× 104). Anal. calcd. (%) for C86H57F9Fe3MnN12O10S2: C 55.06, H 3.06, N 8.96; found: C 55.03, H 3.34, N 
8.28. 
 
[LMn3(HFArPz)3OMn][OTf]2 (3). In the glovebox, a suspension of LMn3(OAc)(OTf)2 (2016 mg, 1.5 
mmol) in DCM (30 mL) was frozen in the cold well. To the thawing suspension was added a thawing 
solution of NaHFArPz (1009 mg, 5.5 mmol) in THF (6 mL). The color changed immediately to pink and 
later to violet, during which the suspension became homogeneous. After stirring for 2 hours, a violet 
suspension was formed to which was added (PhIO, 336 mg, 1.5 mmol) as a solid. Upon addition of PhIO 
the color first changed to pink and after stirring for 16 hours a brown suspension was obtained. The 
solvent was removed under reduced pressure, to yield a brown solid. The solid was suspended in DME 
and stirred for 16 hours. The solid was collected on a bed of Celite (0.5 cm) on a medium porosity glass 
frit, and washed with DME until the filtrate was nearly colorless. The remaining solid was dissolved in a 
minimal of DCM and collected. The solvent was removed under reduced pressure to a brown violet solid 
(1060 mg). The violet solid was suspended in THF and Mn(OTf)2•2MeCN (1010 mg, 2.2 mmol) was 
added as a solid. The suspension was stirred for 24 h and the solvent removed under reduced pressure. To 
the remaining brown/violet solid was added DME (40 mL), and the resulting suspension was stirred for 
16 h, and subsequently filtered over a bed of Celite (0.5 cm) on a medium porosity glass frit. The 
remaining brown solid was dissolved in dichloromethane, filtered, and the solvent removed under reduced 
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pressure to yield a brown solid (1300 mg). The solid was crystallized from acetonitrile/diethyl ether to 
yield [LMn3(PhPz)3OMn][OTf]2 as a brown/violet crystals. Yield 960 mg (34%). X-ray quality crystals 
were obtained by diffusing diethyl ether into a concentrated solution of 2 in acetonitrile. 1H NMR (300 
MHz, CD2Cl2) δ 57.2 (br), 50.3 (s), 34.4 (s), 30.6 (s), 13.8 (s), 10.63 (s), -11.59 (s), -19.43 (s), -32.5 (br). 
19F NMR (282 MHz CD2Cl2) δ -77.47. UV-Vis (CH2Cl2) [ε (M-1 cm-1)]: 248 nm (2.56 × 105), 500 nm 
(3.37 × 103). Anal. calcd. (%) for C86H57F9Mn4N12O10S2: C 55.14, H 3.07, N 8.97; found: C 55.24, H 3.17, 
N 9.14. 
 
[LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4). In the glovebox, to a solution of [LFe3(HFArPz)3OFe][OTf]2 
(100.9 mg; 0.054 mmol) in CH2Cl2 (5.0 mL) was added a suspension 2-(1H-pyrazol-3-yl)-3-phenolate 
(NaOArPzH; 14.8 mg; 0.082 mmol) in CH2Cl2 (1.0 mL). The solution was stirred for ca. 48 h., during 
which the color changed from brown to red/brown. The solution was filtered over a bed of Celite (0.5 cm) 
in a glass pipette and the solvent was removed under reduced pressure to yield a red/brown powder (98.2 
mg). The crude solid was dissolved in CH2Cl2 (5.0 mL) and 400 µL stock solution of 0.12 M AgOTf in 
MeCN was added (AgOTf stock: 61.6 mg in 2 mL). The solution turned green immediately and was 
stirred for 2 hours, before the solution was filtered over a bed of Celite (0.5 cm) in a glass pipette to 
remove metallic Ag. The solvent was removed under reduced pressure to yield of 
[LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4) as a green powder. Yield 95.4 mg (94%). If needed compound 4 
can be crystallized by vapor diffusion of diethyl ether into a concentrated solution of 4 in MeCN (ca. 200 
mg mL-1). 1H NMR (300 MHz, CD2Cl2) δ 149.1 (br), 140.6 (br), 128.3 (br), 112.9 (br), 103.9 (br), 88.4 
(s), 84.7 (br), 82. 5 (s), 81.8 (s), 79.9 (s), 75.4 (s), 69.2 (s), 66.3 (s), 65.1 (s), 62.9 (s), 59.3 (s), 54.7 (s), 
47.3 (s), 38.1 (s), 36.0 (s), 31.9 (s), 28.2 (s), -4.5 (br), -7.7 (br), -11.1 (s), -18.6 (br), -21.1 (s). 19F NMR 
(282 MHz, CD2Cl2) δ -77.1, -78.2, -78.9. UV-Vis (CH2Cl2) [ε (M-1 cm-1)]: 243 nm (1.07 × 105), 355 nm 
(1.17 × 104), 443 nm (8.40 × 103), 596 nm (4.44 × 103). Anal. calcd. (%) for C86H57F8Fe4N12O11S2: C 
55.12, H 3.07, N 8.97; found: C 54.76, H 3.20, N 8.68. 
 
[LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5). In the glovebox, to a solution of [LFe3(HFArPz)3OFe][OTf]2 
(91.6 mg; 0.049 mmol) in CH2Cl2 (5.0 mL) was added a suspension 2-(1H-pyrazol-3-yl)-3-
fluorophenolate (NaOFArPzH; 16.7 mg; 0.084 mmol) in CH2Cl2 (1.0 mL). The solution was stirred for 
ca. 48 h., during which the color changed from brown to red/brown. The solution was filtered over a bed 
of Celite (0.5 cm) in a glass pipette and the solvent was removed under reduced pressure to yield a 
red/brown powder (73.2 mg). The crude solid was dissolved in CH2Cl2 (5.0 mL) and 350 µL stock 
solution of 0.12 M AgOTf in MeCN was added (AgOTf stock: 61.2 mg in 2 mL). The solution turned 
green brown immediately and was stirred for 2 hours, before the solution was filtered over a bed of Celite 
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(0.5 cm) in a glass pipette to remove metallic Ag. The solvent was removed under reduced pressure to 
yield of [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5) as a green/brown powder. Yield 73.4 mg (81%). If 
needed compound 5 can be crystallized by vapor diffusion of diethyl ether into a concentrated solution of 
5 in MeCN (ca. 200 mg mL-1). 1H NMR (300 MHz, CD2Cl2) δ 147.4 (br), 144.0 (br), 129.2 (br), 110.9 
(br), 105.8 (br), 88.8 (s), 87.3 (br), 83.3 (s), 82.5 (s), 80.6 (s), 79.9 (s), 77.4 (s), 68.7 (s), 66.4 (s), 65.2 (s), 
64.3 (s), 60.1 (s), 55.8 (s), 47.2 (s), 40.1 (s), 36.5 (s), 33.1 (s), 28.4 (s), -2.4 (br), -4.5 (br), -8.3 (br), -17.1 
(br), -20.5 (s). 19F NMR (282 MHz, CD2Cl2) δ -50.63, -76.94, -78.17. UV-Vis (CH2Cl2) [ε (M-1 cm-1)]: 
239 nm (1.06 × 105), 347 nm (1.14 × 104), 443 nm (8.23 × 103), 604 nm (4.16 × 103). Anal. calcd. (%) for 
C86H56F9Fe4N12O11S2: C 54.60, H 2.98, N 8.88; found: C 54.61, H 3.25, N 9.07. 
 
[LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6). In the glovebox, to a solution of 
[LFe3(HFArPz)3OMn][OTf]2 (94.6 mg; 0.051 mmol) in CH2Cl2 (5.0 mL) was added a suspension 2-(1H-
pyrazol-3-yl)-3-phenolate (NaOArPzH; 14.2 mg; 0.078 mmol) in CH2Cl2 (1.0 mL). The solution was 
stirred for ca. 48 h., and no clear color change was observed. The solution was filtered over a bed of 
Celite (0.5 cm) in a glass pipette and the solvent was removed under reduced pressure to yield a brown 
powder (83.6 mg). The crude solid was dissolved in CH2Cl2 (5.0 mL) and 400 µL stock solution of 0.12 
M AgOTf in MeCN was added (AgOTf stock: 61.6 mg in 2 mL). The solution turned dark brown 
immediately and was stirred for 2 hours, before the solution was filtered over a bed of Celite (0.5 cm) in a 
glass pipette to remove metallic Ag. The solvent was removed under reduced pressure to yield of 
[LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6) as a brown powder. Yield 80.3 mg (84%). If needed compound 
6 can be crystallized by vapor diffusion of diethyl ether into a concentrated solution of 6 in MeCN (ca. 
200 mg mL-1). 1H NMR (300 MHz, CD2Cl2) δ 164.5 (br), 158.0 (br), 124.3 (br), 114.5 (br), 107.1 (br), 
94.9 (s), 92.5 (s), 88.2 (s), 87.3 (s), 82.5 (s), 75.0 (s), 74.0 (s), 73.3 (s), 70.2 (s), 68.8 (s), 67.9 (s), 62.0 (s), 
60.8 (s), 55.7 (s), -7.1 (br). 19F NMR (282 MHz, CD2Cl2) δ -77.9, -81.2. UV-Vis (CH2Cl2) [ε (M-1 cm-1)]: 
242 nm (2.50 × 105), 450 nm (1.59 × 104). Anal. calcd. (%) for C86H57F8Fe3MnN12O11S2: C 55.15, H 3.07, 
N 8.97; found: C 53.97, H 3.13, N 8.86. 
 
[LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7). In the glovebox, to a solution of 
[LFe3(HFArPz)3OMn][OTf]2 (89.9 mg; 0.048 mmol) in CH2Cl2 (5.0 mL) was added a suspension 2-(1H-
pyrazol-3-yl)-3-fluorophenolate (NaOFArPzH; 16.9 mg; 0.085 mmol) in CH2Cl2 (1.0 mL). The solution 
was stirred for ca. 48 h., during which no apparent color change could be observed. The solution was 
filtered over a bed of Celite (0.5 cm) in a glass pipette and the solvent was removed under reduced 
pressure to yield a red/brown powder (86.3 mg). The crude solid was dissolved in CH2Cl2 (5.0 mL) and 
400 µL stock solution of 0.12 M AgOTf in MeCN was added (AgOTf stock: 61.2 mg in 2 mL). The 
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solution turned dark brown immediately and was stirred for 2 hours, before the solution was filtered over 
a bed of Celite (0.5 cm) in a glass pipette to remove metallic Ag. The solvent was removed under reduced 
pressure to yield of [LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7) as a brown powder. Yield 88.6 mg (97%). 
If needed compound 7 can be crystallized by vapor diffusion of diethyl ether into a concentrated solution 
of 7 in MeCN (ca. 200 mg mL-1). 1H NMR (300 MHz, CD2Cl2) δ 171.7 (br), 162.9 (br), 149.5 (br), 123.7 
(br), 119. 3 (br), 97.3 (s), 92.2 (s), 87.7 (s), 85.0 (s), 80.7 (s), 77.2 (s), 73.6 (s), 73.2 (s0, 71.4 (s), 66.7 (s), 
62.9 (s), 53.9 (s), -4.9 (br). 19F NMR (282 MHz, CD2Cl2) δ -64.6, -77.8, -82.5. UV-Vis (CH2Cl2) [ε (M-1 
cm-1)]: 242 nm (1.46 × 105) 450 nm (8.32 × 103) Anal. calcd. (%) for C86H56F9Fe3Mn12O11S2: C 54.62, H 
2.99, N 8.89; found: C 54.14, H 3.22, N 8.72. 
 
Addition of sPhIO to [LFe3(HFArPz)3OFe][OTf]2 (1). In the glovebox, to a solution of 
[LFe3(HFArPz)3OFe][OTf]2 (56.1 mg; 0.03 mmol) in CH2Cl2 (3.0 mL) was added a solution of sPhIO 
(21.1 mg; 0.06 mmol) in CH2Cl2 (1.0 mL). Upon addition, the color changed immediately to green/black 
and the solution was stirred for 30 min, where after a 10 µL aliquot was taken, from which the ESI-MS 
spectrum was recorded. From the remaining solution, the solvent was removed under reduced pressure to 
yield a green/black solid. The 1H NMR spectrum of the remaining solid was recorded and showed 
complex 4 as the major component of the reaction mixture (Figure S8). This procedure was repeated three 
times to get accurate values on the degree of C(sp2)–H vs. C(sp2)–F activation 1H NMR and ESI-MS. 
 
Addition of sPhIO to [LFe3(HFArPz)3OMn][OTf]2 (2). In the glovebox, to a solution of 
[LFe3(HFArPz)3OMn][OTf]2 (54.1 mg; 0.03 mmol) in CH2Cl2 (3.0 mL) was added a solution of sPhIO 
(19.6 mg; 0.06 mmol) in CH2Cl2 (1.0 mL). Upon addition, the color darkened to dark brown and the 
solution was stirred for 45 min, where after a 5 µL aliquot was taken, from which the ESI-MS spectrum 
was recorded. From the remaining solution, the solvent was removed under reduced pressure to yield a 
green/black solid. The 1H NMR spectrum of the remaining solid was recorded and showed complex 7 as 
the major component of the reaction mixture (Figure S12). This procedure was repeated three times to get 
accurate values on the degree of C(sp2)–H vs. C(sp2)–F activation by 1H NMR and ESI-MS. 
 
Addition of sPhIO to [LMn3(HFArPz)3OMn][OTf]2 (3). In the glovebox, to a solution of 
[LMn3(HFArPz)3OMn][OTf]2 (34.1 mg; 0.018 mmol) in CH2Cl2 (3.0 mL) was added a solution of sPhIO 
(19.6 mg; 0.047 mmol) in CH2Cl2 (1.0 mL). Upon addition, the color darkened to dark brown and the 
solution was stirred for 60 min, where after a 5 µL aliquot was taken, from which the ESI-MS spectrum 
was recorded. From the remaining solution, the solvent was removed under reduced pressure to yield a 
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green/black solid. The 1H NMR spectrum of the remaining solid was recorded, but due to paramagnetic 
broadening by manganese, no useful comparison could be made (Figure S14).  
 
Calibration Curve of Complexes 4 and 5. To get an idea about the extent of C(sp2)–H vs. C(sp2)–F 
bond oxygenation with complex 1, a calibration curve was constructed according to the following 
procedure. In the glovebox, separate equimolar stock solutions of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 
(26.9 mg, 0.014 mmol), and [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (27.1 mg, 0.014 mmol) in CD2Cl2 (3.0 
mL) were prepared. The equimolar solutions (4.76 mM) of complexes 4 and 5 were subsequently mixed 
in varying ratios ranging from 5:1 →	1:5, by combining 100 µL stock solutions of each complex to a 
total volume of 0.6 mL. For example, a 5:1 ratio of complex 4 to 5 was obtained by combining a 500 µL 
stock solution of 4 with a 100 µL stock solution of 5. The 1H NMR of all stock solutions were recorded, 
and their ratio determined by integrating the resonances at 31.8 ppm and 33.0 ppm belonging complexes 4 
and 5 respectively. The calibration curve based on NMR spectroscopy was constructed by plotting the 
experimentally observed ratio (NMR) vs. the ratio in which the complexes were mixed. The calibration 
curve based on mass spectrometry data, was constructed by taken 5 µL aliquots of the NMR samples 
(diluted in 1.5 mL MeCN), and plotting the ratios of the ESI-MS peak at m/z = 787.59 (4) and at m/z = 
796.59 (5), vs. the ratio in which the complexes were mixed. The NMR and ESI-MS data and the 
corresponding calibration curves are shown in Figures S18-S20. 
 
Calibration Curve of Complexes 6 and 7. To get an idea about the extent of C(sp2)–H vs. C(sp2)–F 
bond oxygenation with complex 2, a calibration curve was constructed according to the following 
procedure. In the glovebox, separate equimolar stock solutions of [LFe3(HFArPz)2(OArPz)OMn][OTf]2 
(38.2 mg, 0.02 mmol), and [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (38.9 mg, 0.02 mmol) in CD2Cl2 (3.0 
mL) were prepared. The equimolar solutions (6.79 mM) of complexes 6 and 7 were subsequently mixed 
in varying ratios ranging from 5:1 →	1:5, by combining 100 µL stock solutions of each complex to a 
total volume of 0.6 mL. For example, a 5:1 ratio of complex 4 to 5 was obtained by combining a 500 µL 
stock solution of 4 with a 100 µL stock solution of 5. The 1H NMR of all stock solutions were recorded, 
and their ratio determined by integrating the resonances at 60.3 ppm and 77.6 ppm belonging complexes 6 
and 7 respectively. The calibration curve based on NMR spectroscopy was constructed by plotting the 
experimentally observed ratio (NMR) vs. the ratio in which the complexes were mixed. The calibration 
curve based on mass spectrometry data, was constructed by taken 5 µL aliquots of the NMR samples 
(diluted in 1.5 mL MeCN), and plotting the ratios of the ESI-MS peak at m/z = 787.09 (6) and at m/z = 
796.09 (7), vs. the ratio in which the complexes were mixed. The NMR and ESI-MS data and the 
corresponding calibration curves are shown in Figures S21-S23. 
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Conversion of [LFe3(HFArPz)3OFe][OTf]2 (1) upon reaction with sPhIO. In the glovebox, to a 
solution of [LFe3(HFArPz)3OFe][OTf]2 (9.5 mg; 5.1 µmol) in CD2Cl2 (0.4 mL) was added a solution of 
sPhIO (3.2 mg; 9.4 µmol) in CH2Cl2 (0.3 mL). Upon addition, the color changed immediately to black and 
the solution was stirred for 60 min. The contents were transferred to a NMR tube, and a capillary was 
added containing a solution of cobaltocene (7.33 mM in CD2Cl2). The conversion was recorded by 
comparing the combined integrals at 47.4, 36.0, 31.8 and 28.2 ppm to the integrals obtained from an 
authentic solution of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (9.2 mg; 4.9 µmol) in 0.7 mL CD2Cl2, 
containing the same capillary. The conversion was determined to between 40-50%. Based on the integrals 
ca. 35% is attributed to [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4), whereas the remaining 10% is attributed 
to the formation of [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5) and of [LFe3(HFArPz)3OFe(F)][OTf]2 based 
on the observed product distributions (Figure S28 and S29). 
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Figure S1. 1H NMR spectrum (400 MHz) of sodium 3-(2-fluorophenyl)pyrazolate (NaHFArPz) in 
CD3CN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. 13C NMR spectrum (101 MHz) of sodium 3-(2-fluorophenyl)pyrazolate (NaHFArPz) in 
CD3CN. 
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Figure S3. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)3OFe][OTf]2 (1) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)3OMn][OTf]2 (2) in CD2Cl2. 
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Figure S5. 1H NMR spectrum (300 MHz) of [LMn3(HFArPz)3OMn][OTf]2 (3) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4) in CD2Cl2. 
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Figure S7. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8. Comparison of the 1H NMR spectrum of the crude reaction mixture with the 1H NMR 
spectrum of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (5) in CD2Cl2. 
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Figure S9. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4; 4.76 mM) and 
[LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5; 4.76 mM) mixed in known ratios to a volume of 0.6 mL in 
CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S10. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6) in CD2Cl2. 
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Figure S11. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7) in CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S12. Comparison of the 1H NMR spectrum of the crude reaction mixture with the 1H NMR 
spectrum of a mixture of [LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6) and 
[LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7) a 2:4 ratio in CD2Cl2.  
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Figure S13. 1H NMR spectrum (300 MHz) of [LFe3(HFArPz)2(OArPz)OMn][OTf]2 (6; 6.79 mM) and 
[LFe3(HFArPz)2(OFArPz)OMn][OTf]2 (7; 6.85 mM) mixed in known ratios to a volume of 0.6 mL in 
CD2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S14. 1H NMR spectrum (300 MHz) of the crude reaction mixture upon treating 3 with sPhIO for 
60 minutes.  
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Figure S15. Cyclic voltammogram (CV) of [LFe3(HFArPz)3OFe][OTf]2 (1) at a scan rate of 100 mV s −1. 
The CV was recorded in CH2Cl2 at a concentration of 2 mM, with glassy carbon, Pt-wire, and Ag-wire as 
the working, counter, and reference electrodes, respectively. nBu4NPF6 (0.1 M) was used as the 
supporting electrolyte. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S16. Cyclic voltammogram (CV) of [LFe3(HFArPz)3OMn][OTf]2 (2) at a scan rate of 100 mV s 
−1. The CV was recorded in CH2Cl2 at a concentration of 2 mM, with glassy carbon, Pt-wire, and Ag-wire 
as the working, counter, and reference electrodes, respectively. nBu4NPF6 (0.1 M) was used as the 
supporting electrolyte.  
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Figure S17. Cyclic voltammogram (CV) of [LMn3(HFArPz)3OMn][OTf]2 (3) at a scan rate of 100 mV s 
−1. The CV was recorded in CH2Cl2 at a concentration of 2 mM, with glassy carbon, Pt-wire, and Ag-wire 
as the working, counter, and reference electrodes, respectively. nBu4NPF6 (0.1 M) was used as the 
supporting electrolyte. 
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Figure S18. (A and B) Electrospray ionization mass spectrum (ESI-MS) of an aliquot of the crude 
reaction mixture after treating 1 with sPhIO (2 equiv.) for 30 minutes in CH2Cl2. (C) Simulated mass 
spectrum and isotope distribution pattern for 4 [C84H57F2Fe4N12O5]2+. (D) Simulated mass 
spectrum and isotope distribution pattern for and 5 [C84H56F3Fe4N12O5]2+.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
(C) (D) 
 S23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S19. ESI-MS spectra of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (4; 4.76 mM, m/z = 787.59) and 
[LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (5; 4.76 mM; m/z = 796.59) mixed in known ratios in MeCN. 
[LFe3(HFPhPz)2(OArPz)OFe][OTf]2 
5:1 
4:2 
3:3 
2:4 
1:5 
[LFe3(HFPhPz)2(OFArPz)OFe][OTf]2 
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Figure S20. Experimentally determined C(sp2)–F to C(sp2)–H ratio (green dots) by mass spectrometry 
(A) and 1H NMR spectroscopy (B). Data points were obtained by either determining the ratio of the 
relative intensities of the MS peaks at m/z = 787.59 (4) and at m/z = 796.59 (5), or by integrating the 1H 
NMR resonances at 31.8 ppm and 33.0 ppm belonging to complexes 4 and 5 respectively. The blue dots 
and dashed black trace (R2 = 0.99) represent the calibration curve obtained by recording the ratios of the 
1H NMR signals or MS intensities after mixing known concentrations of complexes 4 and 5. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
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Figure S21. (A and B) Electrospray ionization mass spectrum (ESI-MS) of an aliquot of the crude 
reaction mixture after treating 2 with sPhIO (2 equiv.) for 45 minutes in CH2Cl2. (C) Simulated mass 
spectrum and isotope distribution pattern for 6 [C84H57F2Fe3MnN12O5]2+. (D) Simulated mass 
spectrum and isotope distribution pattern for and 7 [C84H56F3Fe3MnN12O5]2+. Note: from the 
isotope distribution pattern, it is evident that there is a small impurity present at m/z = 788.59, which is 
the starting material 2. However, complex 2 was not observed in the 1H NMR spectrum of the crude 
reaction mixture. 
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Figure S22. ESI-MS spectra of [LFe3(HFArPz)2(OArPz)OFe][OTf]2 (6; 6.79 mM, m/z = 787.09) and 
[LFe3(HFArPz)2(OFArPz)OFe][OTf]2 (7; 6.85 mM; m/z = 796.09) mixed in known ratios in MeCN. 
[LFe3(HFPhPz)2(OArPz)OMn][OTf]2 
5:1 
4:2 
3:3 
2:4 
1:5 
[LFe3(HFPhPz)2(OFArPz)OMn][OTf]2 
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Figure S23. Experimentally determined C(sp2)–F to C(sp2)–H ratio (green dots) by mass spectrometry 
(A) and 1H NMR spectroscopy (B). Data points were obtained by either determining the ratio of the 
relative intensities of the MS peaks at m/z = 787.09 (6) and at m/z = 796.09 (7) , or by integrating the 1H 
NMR resonances at 60.3 ppm and 77.6 ppm belonging to complexes 6 and 7 respectively. The blue dots 
and dashed black trace (R2 = 0.99) represent the calibration curve obtained by recording the ratios of the 
1H NMR signals or MS intensities after mixing known concentrations of complexes 6 and 7. 
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Figure S24. (A and B) Electrospray ionization mass spectrum (ESI-MS) of an aliquot of the crude 
reaction mixture after treating 3 with sPhIO (2 equiv.) for 60 minutes in CH2Cl2. (C) Simulated mass 
spectrum and isotope distribution pattern for 8 [C84H57F2Mn4N12O5]2+. (D) Simulated mass 
spectrum and isotope distribution pattern for and 9 [C84H56F3Mn4N12O5]2+.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
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Figure S25. Crystal structure of [LFe3(HFArPz)3OFe][OTf]2 (1). Thermal ellipsoids are shown at the 
50% probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents molecules 
are not shown for clarity. 
 
Special refinement details for complex 1. Compound [LFe3(HFArPz)3OFe][OTf]2 (1) crystallizes in the 
monoclinic space group P21/c with one molecule in the asymmetric unit along with two triflate anion, 0.4 
molecules of diethyl ether, and 1.2 molecules of acetonitrile. Two of the pyrazolate phenyl rings are 
disordered by rotation, where one is also disordered by vibration, giving rise to ortho disordered fluorine 
substituents. Both disordered fluorine’s were modeled as two-component disorder and refined freely to 
occupancies of 0.63 and 0.37 (ring 1) and 0.59 and 0.41 for the fluorine substituent and phenyl ring on the 
second pyrazolate. The first triflate anion was modeled as a two-component disordered and refined freely 
to occupancies of 0.80 and 0.20 respectively. The second triflate counter ion was modelled as a three-
component disorder with occupancies of 0.33, 0.36 and 0.31. All disordered triflates were refined with the 
help of similarity restraints on the 1,2- and 1,3-distances and displacement parameters. One acetonitrile 
molecule (occupancy 0.7) is disordered is disordered over three positions and refined with occupancies of 
0.22, 0.22 and 0.26. This heavily discorded acetonitrile molecule did not refine anisotropically and all 
atoms were modelled with ISOR restraints, and with distance restraints on the 1,2- and 1,3-distances. All 
the triflate counter ions, acetonitrile molecules, and diethyl ether molecules were refined with the help of 
enhanced rigid bond restraints for anisotropic displacement parameters. In addition, all atoms were 
refined with rigid bond restraints, and restrained to have similar Uij values.
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Figure S26. Crystal structure of [LFe3(HFArPz)3OMn][OTf]2 (2). Thermal ellipsoids are shown at the 
50% probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents molecules 
are not shown for clarity. 
 
Special refinement details for complex 2. Complex 2 crystallizes in the monoclinic space group C2c 
with one molecule in the asymmetric unit along with two triflate anions, 1.34 molecules of diethyl ether 
and 3.24 molecules of acetonitrile. One the pyrazolate phenyl rings is disordered by rotation, giving rise 
to ortho disordered fluorine substituents. Both disordered fluorine atoms were modeled as a two-
component disorder and refined freely to occupancies of 0.57 and 0.43 respectively. One of the triflate 
anions was disordered over two positions, and refined freely with occupancies of 0.41 and 0.59. The 
diethyl ethyl and acetonitrile are located in large solvent accessible voids and highly disordered. The 
diethyl ether was modeled over five positions and the acetonitrile was modeled over six positions. All 
disordered atoms were refined with the help of similarity restraints on the 1,2- and 1,3-distances and 
displacement parameters as well as enhanced rigid bond restraints for anisotropic displacement 
parameters 
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 Figure S27. Crystal structure of [LMn3(HFArPz)3OMn][OTf]2 (3). Thermal ellipsoids are shown at 
the 50% probability level. Hydrogen atoms, outer sphere counter ions, and co-crystallized solvents 
molecules are not shown for clarity. 
 
Special refinement details for complex 3. Compound [LMn3(HFArPz)3OFe][OTf]2 (3) crystallizes in 
the monoclinic space group P21/c with one molecule in the asymmetric unit along with two triflate anion, 
1.2 molecules of diethyl ether, and 2.3 molecules of acetonitrile. Two of the pyrazolate phenyl rings are 
discorded by rotation, giving rise to ortho disordered fluorine substituent. Both disordered fluorine’s were 
modeled as two-component disorder and refined freely to occupancies of 0.66 and 0.33 (ring 1) and 0.73 
and 0.27 for the fluorine substituent on the second pyrazolate phenyl ring. One of triflate anions is 
disordered and was modelled as a three-component disorder with fixed occupancies of 0.10, 0.30 and 0.60 
respectively. The disordered triflate was refined with the help of similarity restraints on the 1,2- and 1,3-
distances and displacement parameters. One diethyl ether molecule is disordered with two acetonitrile 
molecules and was modelled as a three-component disorder with occupancies of 0.20 for the diethyl ether 
molecule and 0.40 for both acetonitrile molecules. The co-crystallized diethyl ether molecules were 
refined, while restraining the 1,2- and 1,3-distances. All triflate counter ions and solvent molecules were 
refined with the help of enhanced rigid bond restraints for anisotropic displacement parameters.  
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Figure S28. 1H NMR spectrum (300 MHz) of the crude reaction mixture upon treating 1 with sPhIO for 
45 minutes, in the presence of an internal standard (CoCp2; 7.33mM) in a glass capillary.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S29. 1H NMR spectrum (300 MHz) of 4 in the presence of an internal standard (CoCp2; 71.4 mM) 
in a glass capillary.  
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Table S1. Selected bond angles and distances for complexes 1–3. 
 
Bond Distance (Å) Complex 
 1 2 a 3 
M1–O1 1.915(3) 1.978(4) 2.2244(13) 
M2–O1 1.938(3) 1.958(4) 1.8977(12) 
M3–O1 2.144(3) 2.107(4) 1.8914(13) 
M1–N13 2.090(3) 2.101(5) 2.3136(16) 
M2–N23 2.072(4) 2.149(5) 2.0128(16) 
M3–N33 2.113(3) 2.117(5) 2.0050(16) 
M4–N14 2.127(4) 2.172(6) 2.1390(16) 
M4–N24 2.131(3) 2.172(5) 2.1913(15) 
M4–N34 2.090(3) 2.148(5) 2.1888(17) 
M4-N1 2.120(4) - 2.2030(18) 
N13–N14 1.374(5) 1.383(7) 1.369(2) 
N23–N24 1.378(5) 1.382(6) 1.368(2) 
N33–N34 1.378(4) 1.365(7) 1.371(2) 
M4–O1 2.048(3) 1.996(4) 2.0901(13) 
    
Bond Angles (º)    
N14–Mn4–N24 125.74(14) 121.2(2) 110.74(6) 
N24–Mn4–N34 114.38(13) 117.9(2) 127.31(6) 
N34–Mn4–N14 118.13(14) 120.71(19) 118.94(6) 
O1–Mn4–N1 175.06(14) - 171.62(6) 
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Table S2. Crystal and refinement data for complexes 1–3. 
 Complex 1 Complex 2 Complex 3 
CCDC    
Empirical 
formula C92H67.6F9Fe4N14.2O10.4S2 
C97.88H80.13N15.23O11.34F9S2
Fe3Mn 
C97.4H78.9F9Mn4N15.3O11.2S2 
Formula 
weight (g/mol) 1996.92 2108.82 2097.73 
T (K) 100 100 100 
Radiation MoKα (λ = 0.71073) CuKα (λ = 1.54178) MoKα (λ = 0.71073) 
a (Å) 22.7641(10) 24.5890(14) 22.9197(16) 
b (Å) 17.3323(8) 30.9989(16) 17.2938(12) 
c (Å) 24.0740(11) 24.9769(12) 24.1821(17) 
α (deg) 90 90 90 
β (deg) 97.1460(10) 95.136(3) 96.961(4) 
γ (deg) 90 90 90 
V (Å3) 9424.7(7) 18961.8(17) 9514.4(12) 
Z 4 8 4 
Cryst. syst. monoclinic monoclinic monoclinic 
Space group P21/c C2/c P21/c 
ρcalcg (cm3) 1.407 1.477 1.464 
2 σ range (deg) 4.7 to 57.398 4.598 to 148.99 2.902 to 72.944 
Crystal 
size/mm 0.33 × 0.24 × 0.17 0.25 × 0.22 × 0.11 0.20 × 0.20 × 0.20 
µ (mm-1) 0.730 5.820 0.649 
GOF 1.068 1.047 1.061 
R1, wR2 (I> 
2σ (I)) R1 = 0.0777, wR2 = 0.2204 R1 = 0.0950, wR2 = 0.2287 R1 = 0.0614, wR2 = 0.1621 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 S35 
 
References 
[S1] C.-Y. Huang, A. G. Doyle, J. Am. Chem. Soc. 2012, 134, 9541-9544. 
[S2] F. Song, C. Wang, J. M. Falkowski, L. Ma, W. Lin, J. Am. Chem. Soc. 2010, 132, 15390-15398. 
[S3] D. Macikenas, E. Skrzypczak-Jankun, J. D. Protasiewicz, J. Am. Chem. Soc. 1999, 121, 7164-
7165. 
[S4] G. de Ruiter, N. B. Thompson, D. Lionetti, T. Agapie, J. Am. Chem. Soc. 2015, 137, 14094-
14106. 
[S5] C. Liu, K. Leftheris, J. Lin, Preparation of benzothiazole and azabenzothiazole compounds useful 
as kinase inhibitors, WO2007016392A2, Bristol-Myers Squibb Company, USA . 2007, 95pp. 
[S6] G. de Ruiter, N. B. Thompson, M. K. Takase, T. Agapie, J. Am. Chem. Soc. 2016, 138, 1486-
1489. 
[S7] E. Y. Tsui, J. S. Kanady, M. W. Day, T. Agapie, Chem. Commun. 2011, 47, 4189-4191. 
[S8] APEX-II, Version 2 User Manual, M86-E01078, Bruker Analytical X-ray Systems,, Madison, WI, 
June 2006. 
[S9] G. M. Sheldrick, “SADABS (version 2008/1): Program for Absorption Correction for Data from 
Area Detector Frames”, , University of Göttingen, 2008. 
[S10] G. Sheldrick, Acta Crystallogr., Sect. A 1990, 46, 467-473. 
[S11] G. M. Sheldrick, Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112-122. 
[S12] P. Müller, Crystallogr. Rev. 2009, 15, 57-83. 
 
